Create Free Account

By creating account you will get access to hot stocks & personalised emails

Imagion Biosystems Ltd

Healthcare AU IBX

0.019AUD
0.001(5.56%)

Last update at 2024-12-19T05:11:00Z

Day Range

0.020.02
LowHigh

52 Week Range

0.020.38
LowHigh

Fundamentals

  • Previous Close 0.02
  • Market Cap1.26M
  • Volume581917
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-5.48390M
  • Revenue TTM5.92M
  • Revenue Per Share TTM0.18
  • Gross Profit TTM 0.15M
  • Diluted EPS TTM-0.18

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -9.80721M -6.02471M -5.36401M -3.43251M -8.34001M
Minority interest - - - - -
Net income -9.80919M -8.63921M -7.79510M -5.46619M -8.34001M
Selling general administrative 5.52M 3.76M 2.82M 1.82M 3.97M
Selling and marketing expenses - - - - -
Gross profit 0.47M 0.23M 0.21M 0.41M 0.19M
Reconciled depreciation 1.11M 0.40M 0.36M 0.14M 0.21M
Ebit -9.80522M -6.02040M -5.35754M -3.42335M -8.33226M
Ebitda -8.69704M -5.61597M -4.99697M -3.28136M -8.11847M
Depreciation and amortization 1.11M 0.40M 0.36M 0.14M 0.21M
Non operating income net other - - - - -
Operating income -9.80522M -6.02040M -5.35754M -3.42335M -8.95716M
Other operating expenses 12.70M 8.87M 7.96M 5.88M -
Interest expense 0.00198M 0.00430M 0.00647M 0.00916M 0.00775M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.03M 0.00890M 0.00534M 0.04M 0.44M
Net interest income -0.14449M 0.00272M -0.00113M 0.01M 0.03M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.00198M 2.61M 2.43M 2.03M 0.00000M
Total revenue 0.47M 0.23M 0.21M 0.41M 0.19M
Total operating expenses 12.70M 8.87M 7.96M 5.88M 9.15M
Cost of revenue - - - - 0.00000M
Total other income expense net -0.00198M -0.00430M -0.00647M -0.00916M 0.62M
Discontinued operations - - - - -
Net income from continuing ops -9.80721M -6.02471M -5.36401M -3.43251M -8.34001M
Net income applicable to common shares -9.80721M -6.02471M -5.36401M -3.43251M -8.34001M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 4.59M 9.98M 14.12M 14.12M 4.87M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.30M 0.13M 0.17M 0.10M 0.07M
Total liab 6.46M 5.30M 0.81M 1.21M 1.90M
Total stockholder equity -4.68546M 4.68M 13.31M 12.91M 2.97M
Deferred long term liab - - - - -
Other current liab -5.13582M 0.37M 0.33M 0.25M 0.03M
Common stock 59.31M 56.83M 56.83M 51.32M 36.90M
Capital stock - 56.83M 56.83M 51.32M 36.90M
Retained earnings -68.90681M -55.84146M -46.03425M -40.00955M -34.64554M
Other liab - 0.00190M 0.00303M 0.00154M -
Good will - - - - -
Other assets - - - - -
Cash 0.23M 4.45M 13.39M 13.20M 3.40M
Cash and equivalents - - - 13.20M 3.40M
Total current liabilities 5.36M 1.73M 0.78M 0.90M 1.28M
Current deferred revenue - - - - 0.28M
Net debt 6.91M 0.16M -13.34775M -12.53957M -2.52493M
Short term debt 3.55M 1.04M 0.02M 0.36M 0.26M
Short long term debt - - - - -
Short long term debt total 7.14M 4.60M 0.05M 0.66M 0.88M
Other stockholder equity - 0.88M 0.35M 1.60M 0.71M
Property plant equipment - 4.99M 0.35M 0.69M 1.30M
Total current assets 0.60M 4.99M 13.77M 13.43M 3.57M
Long term investments - - - - -
Net tangible assets - 4.68M 13.31M 12.91M 2.97M
Short term investments - - - - -
Net receivables 0.07M 0.09M 0.03M 0.07M 0.00007M
Long term debt - - - - -
Inventory - 0.32M 0.17M - 0.10M
Accounts payable 1.59M 0.33M 0.43M 0.29M 0.71M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 4.92M 3.69M 2.51M 1.60M 0.71M
Additional paid in capital - - - - -
Common stock total equity - - - 51.32M 36.90M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - 1.30M
Deferred long term asset charges - - - - -
Non current assets total 3.98M 4.99M 0.35M 0.69M 1.30M
Capital lease obligations - 4.60M 0.05M 0.66M 0.88M
Long term debt total - 3.56M 0.03M 0.30M 0.62M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.46873M -0.31009M -0.00786M -0.01235M -0.08357M
Change to liabilities 0.00000M 0.08M -0.18604M -0.29891M 0.37M
Total cashflows from investing activities -0.46873M -0.31009M -0.00786M -0.01235M -0.08357M
Net borrowings -0.96482M -0.35925M -0.24681M -0.03540M -0.12849M
Total cash from financing activities -0.96206M 5.15M 14.52M 3.33M 4.10M
Change to operating activities - - - 0.01M 0.29M
Net income -9.80919M -6.02471M -5.37047M -3.44166M -8.34001M
Change in cash -8.94767M 0.19M 9.80M -0.96538M -2.50573M
Begin period cash flow 13.39M 13.20M 3.40M 4.37M 6.87M
End period cash flow 4.45M 13.39M 13.20M 3.40M 4.37M
Total cash from operating activities -8.70101M -5.06849M -4.62309M -4.18204M -6.56721M
Issuance of capital stock 0.00276M 5.51M 16.11M 3.37M 4.29M
Depreciation 1.11M 0.40M 0.36M 0.14M 0.21M
Other cashflows from investing activities 0.04M -0.09126M -0.09126M -0.09126M -0.09126M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables -0.19767M -0.03413M -0.06600M -0.02090M -0.04458M
Sale purchase of stock 0.00276M -0.00611M -1.34008M -0.01331M -0.05419M
Other cashflows from financing activities -0.96482M -0.35925M -0.24681M -0.03540M -0.12849M
Change to netincome 0.65M 0.50M 0.63M -0.58547M 0.94M
Capital expenditures 0.51M 0.22M 0.00786M 0.01M 0.08M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 2.55M 2.63M 2.20M 2.08M 0.07M
Stock based compensation - - - - -
Other non cash items 8.70M 5.62M 5.00M 3.29M 8.13M
Free cash flow -9.20833M -5.28732M -4.63095M -4.19440M -6.65078M

Peer Comparison

Sector: Healthcare Industry: Diagnostics & Research

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
IBX
Imagion Biosystems Ltd		 0.001 5.56% 0.02 - - 0.21 3.84 2.47 -1.9016
SHL
Sonic Healthcare Ltd		 -0.42 1.50% 27.50 26.26 26.74 1.51 1.72 1.95 10.52
HLS
Healius Ltd		 -0.025 1.75% 1.40 - 23.15 0.58 0.99 1.47 10.14
IDX
Integral Diagnostics Ltd		 -0.08 2.68% 2.90 - 27.70 1.49 2.37 2.19 152.82
ACL
Australian Clinical Labs Ltd		 -0.12 3.32% 3.49 28.83 18.52 1.00 3.87 1.41 5.71

Reports Covered

Stock Research & News

View All

Profile

Imagion Biosystems Limited provides medical imaging technologies using magnetic resonance. It has activities in nanotechnology; biotechnology; cancer diagnostics; and superparamagnetic relaxometry. The company develops MagSense, which is in Phase I clinical trials for the treatment of HER2 breast cancers, as well as in preclinical stage to treat prostate, ovarian, brain, and pancreatic cancer. It also develops PrecisionMRX, an iron oxide nanoparticle to detect cancer. The company has a collaborative research program with Patrys Limited and The University of Sydney. Imagion Biosystems Limited was incorporated in 2016 and is based in South Melbourne, Australia.

Imagion Biosystems Ltd

Level 4, Melbourne, VIC, Australia, 3205

Key Executives

Name Title Year Born
Mr. Robert Romeo Proulx Exec. Chairman, Pres & CEO 1958
Mr. Geoff Hollis CFO & Company Sec. NA
Dr. Yalia Jayalakshmi Ph.D. Chief Devel. Officer NA
Mr. Robert Romeo Proulx Interim Executive Chairman 1958
Mr. Geoff Hollis AGIA, BComm, CA CFO & Company Secretary NA
Mr. Robert Romeo Proulx Interim Executive Chairman 1958
Mr. Geoff Hollis AGIA, BComm, CA CFO & Company Secretary NA
Mr. Robert Romeo Proulx Interim Executive Chairman 1958
Mr. Geoff Hollis AGIA, BComm, CA CFO & Company Secretary NA
Mr. Robert Romeo Proulx Interim Executive Chairman 1958

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

ISO Certified Market Research

Kalkine Solutions Private Limited, authorized representative of Kalkine Pty Ltd, holds ISO 27001:2022 certification bearing Certificate No.- IC-IS-2404072

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.